The present study was conducted as a preliminary evaluation of toxicologic and carcinogenic risks of copper gluconate and to determine its optimal dose for use in an upcoming study utilizing the medium-term multi-organ carcinogenesis protocol. Male BrlHan:WIST@Jcl (GALAS) rats were initially treated with N-nitrosodiethylamine, Nmethylnitrosourea, 1,2-dimethylhydrazine, N-butyl-N-(4-hydroxybutyl)-nitrosamine and 2,2'-dihydroxy-di-
Introduction
Copper plays an important role in biological systems. Copper-containing compounds are involved in oxidationreduction reactions and react directly with molecular oxygen to produce reactive oxygen species 1, 2 . By virtue of its transition metal nature, copper plays catalytic roles in oxygen-dependent reactions and also is an integral part of many metalloenzymes, such as ceruloplasmin, cytochrome oxidase, superoxide dismutase, ascorbate oxidase and tyrosinase 3, 4 . However, copper and copper-containing compounds become toxic, when their concentrations are too high for cells to handle 5, 6 . In addition, copper-mediated oxidative DNA damage induction has been reported for compounds such as catechin, catechol, ortho-phenylphenol and pentachlorophenol, which generate oxidative DNA damage, , in the presence of Cu(II) in vitro [7] [8] [9] [10] . A high concentration of copper in the liver increases hepatocyte proliferation and induces not only liver 8-OHdG, but also hepatocellular carcinoma in Long Evans Cinnamon (LEC) rats in vivo [11] [12] [13] . These findings lead to a concern that copper-containing compounds may have carcinogenic risks, but this has not as yet been sufficiently evaluated.
Copper gluconate is widely used as a nutritional enhancer of supplements, candies and beverages in the United States 14 . In the European Union, it is also extensively used as a food ingredient 15 . In Japan, copper gluconate was designated as a food additive to supplement copper for formula-fed infants in 1983, and currently its use is limited to breastmilk substitutes 16 , but it is expected to be approved as a food with nutritional functions. Its usage will thus be increased, requiring its toxicologic and carcinogenic risks to be evaluated.
Mutagenicity of copper gluconate has been shown negative by the Ames test 17 , while a repeat-dose toxicity study using rats revealed hepatic toxicity at high doses 5 . Its carcinogenicity, however, remains unclear. In the above context, we plan to evaluate the carcinogenic risks of copper gluconate in vivo using a medium-term multi-organ carcinogenesis model [18] [19] [20] . The model has clear benefits for examining the modifying effects of chemicals on carcinogenesis in multiple organs in a single experiment within a relatively short experimental period, and the results obtained have been shown to be in good agreement with those of classic long-term carcinogenicity studies [18] [19] [20] . Before starting such an assessment, the present study was conducted as a preliminary evaluation of the toxicologic and carcinogenic risks of copper gluconate and to determine its optimal dose for use in the medium-term multi-organ carcinogenesis protocol. To elucidate these risks and their mechanisms, we histopathologically evaluated proliferative and nonproliferative lesions in all major organs/tissues, and performed immunohistochemical staining of 8-OHdG and proliferating cell nuclear antigen (PCNA) in the liver. Excess intracellular copper may be bound to metallothionein (MT). MT functions include intracellular metal metabolism/ storage, metal donation, metal detoxification and reduction of oxidants 21 . MT may play defensive roles against the risks induced high copper intake, therefore, we also additionally assessed changes of MT in the liver in this study.
Materials and Methods
The experimental protocols were approved by the Animal Experimentation Committee of the Sasaki Institute prior to their execution. 
Animals
A total of 16 male BrlHan:WIST@Jcl (GALAS) rats, 5 weeks old, were generously provided by CLEA Japan, Inc. (Tokyo, Japan). Rats were housed in plastic cages, 1-3 per cage, with paper chips for bedding in an air-conditioned room at 25 ± 5°C and 50 ± 10% humidity on a 12 hour dark/ light cycle. They were acclimatized for 1 week before the experiment and allowed free access to CE-2 basal diet (CLEA Japan) and tap water throughout the acclimation and experimental periods, unless the protocol requested the administration of special diets and / or drinking fluids.
Experimental design
The experimental design is presented in Fig. 1 . Rats were randomly allocated to 6 groups of 1-3 animals. All rats w e r e g i v e n a c o m b i n e d t r e a t m e n t w i t h a s i n g l e intraperitoneal (i.p.) administration of 100 mg/kg body wt of D E N a t t h e c o m m e n c e m e n t , f o l l o w e d b y 4 i . p . administrations of 20 mg/kg body wt of MNU during the first 2 weeks and 4 subcutaneous (s.c.) injections of 40 mg/ kg body wt of DMH during the second 2 weeks. BBN, 0.05%, was administered in the drinking water for the first 2 weeks and 0.1% DHPN for the second 2 weeks during the initial 4-week period for the carcinogenic initiation. These treatments are in accordance with the medium-term multiorgan carcinogenesis protocol [18] [19] [20] . In addition, rats were fed a diet containing copper gluconate at 0, 1000, 3000, 4800, 6000 (3 animals each) or 12000 ppm (1 animal) from the commencement for 13 weeks. These doses were decided after reviewing dose toxicity studies in the literature 5, 6 . Bodyweight and food consumption were measured weekly. All animals were sacrificed under light ether anesthesia at the end of week 13 and subjected to a complete autopsy. After careful macroscopic observation, blood was taken from the abdominal aorta to obtain serum. Urine was taken from the urinary bladder. Major organs and tissues were removed, and the liver was weighed. Sections of 5 mm thickness from left lateral, right lateral and right medial lobes of the liver were immediately cut, fixed in 10% neutrally buffered formalin, embedded in paraffin and prepared into appropriate numbers of 4-µm thick specimens.
Measurement of copper concentration
Copper concentrations in serum, urine and liver tissue were measured with an atomic absorption spectrometer.
H i s t o p a t h o l o g i c a l , h i s t o c h e m i c a l a n d immunohistochemical staining
Routine hematoxylin-eosin (HE) stained specimens were prepared for histopathological evaluation. Copper in the liver tissue was demonstrated by the Rodanin method 22 .
Immunohistochemical stainings for putative preneoplastic, glutathione S-transferase placental form (GST-P) positive foci of cellular alteration 23 , MT 24 , PCNA 25 and 8-OHdG 26 were performed by the avidin-biotin complex (ABC) method (Vector Laboratories Inc., California, USA). For this purpose, liver sections were deparaffinized and treated with 0.3% H 2 O 2 for 15 min at room temperature, then primary antibodies against GST-P (Medical and Biological Laboratories Co., Ltd., Aichi, Japan; ×100 dilution), MT (Dako Japan Inc., Kyoto, Japan; ×50 dilution) and PCNA (Dako; ×100 dilution) were applied for 1 h at room temperature. After several washes, the sections were then treated with a biotin-labeled secondary antibody for 30 min at room temperature, followed by incubation with peroxidase-conjugated avidin for 30 min at room temperature. Then, the slides were incubated in 0.04% diaminobenzidine solution. In the case of 8-OHdG, liver sections were treated with 10% zinc sulfate solution (95°C, 30 min) and 2 M HCl (37°C, 30 min) in addition to 0.3% H 2 O 2 and incubated with a primary antibody against 8-OHdG (Nikken Seil Co., Ltd., Tokyo, Japan; ×100 dilution). Numbers and areas of GST-P positive lesions, and 8-OHdG and PCNA positive indices were measured with the aid of an image analyzer IPAP (Image Processor for Analytical Pathology), Sumika Technoservice Co., Tokyo, Japan.
Statistical analysis
Data were statistically evaluated by Dunnett's test after one-way analysis of variance (ANOVA), and p-values less than 0.05 were considered to be statistically significant.
Results
All animals survived until their scheduled sacrifice with relatively healthy conditions. Food consumption was similar among groups (data not shown). Black stool was, however, found in rats exposed to copper gluconate of 3000 ppm or greater, and the incidence increased proportionally with increasing dose (data not shown). There was no significant difference in bodyweight during, or at the end of the study among groups (Fig. 2, Table 1 ). The absolute and relative liver weights were also similar among groups, but appeared to increase in the 12000 ppm group which consisted of 1 rat ( Table 1 ). The livers were macroscopically normal in all groups and without copper gluconate-related histological changes in the 0-4800 ppm groups. Slight or moderate granulomas were scattered in the 6000 ppm group livers. Furthermore, marked diffuse granulomas and hepatocellular necrosis were observed in the 12000 ppm group liver (Fig. 3 , Table 2 ). These granulomas consisted mainly of mononuclear cells (macrophages and lymphocytes), but were different from microgranuloma which is occasionally 1  0  3  3  0  0  0  2  1000  3  3  0  0  0  3  3000  3  3  0  0  0  4  4800  3  3  0  0  0  5  6000  3  0  2  1  0  6  12000  1  0  0  0  1 Grade of changes: -; none, ±; slight, +; moderate, ++; marked. Fig. 3 . Granuloma in the 12000 ppm group liver (HE stained, × 400). observed as a spontaneous finding in rat livers at this age.
No copper gluconate-related alterations were detected either macroscopically or histologically in the other major organs/ tissues of any animal (data not shown). Serum and urine copper concentrations in the 0 to 3000 and 4800 ppm groups, respectively, were within a similar range, but the concentrations tended to be higher in the 6000 ppm group followed by a further increase in the 12000 ppm group (Table 3 ). The liver copper concentrations was determined for only 1 rat in each dose group. It was similar between the 0 and 3000 ppm groups, appeared to increase in the 6000 ppm group and was higher still in the 12000 ppm group (Table 3) .
Liver copper staining was absent in the 0 and 1000 ppm groups, and slight in the 3000 ppm group. It became evident in rats exposed to 4800 ppm or greater, the grade being increased proportionally with the increasing dose of copper gluconate (Table 3) . In all positive cases, copper was detected as red granules in hepatocyte cytoplasm and was distributed diffusely in the liver tissue (Fig. 4A) . MT was almost absent but it was observed in the cytoplasm of one or two hepatocytes in the 0 ppm group. Slight centrilobular staining was seen in the 1000 and 3000 ppm groups, the latter being a little more evident than the former. Intense centrilobular or diffuse staining was demonstrated in the 4800 and 6000 ppm groups, and more intense diffuse staining was observed in the 12000 ppm group (Fig. 4B , Table 4 ).
In all groups, 8-OHdG was more or less detected in hepatocyte nuclei. Although the 8-OHdG positive index was not substantially different among the 0 to 4800 ppm groups, it was higher in the 6000 ppm group and further increased in the 12000 ppm group which consisted of 1 rat (Figs. 4C and 4D, Table 4 ). The PCNA positive index rose in the 3000 ppm group, and it was significantly increased in the 4800 ppm or greater groups (Table 4) . Sizes of GST-P positive lesions were not different among groups, but the number and thus occupancy appeared to increase in the 12000 ppm group which consisted of 1 rat (Table 5) .
Discussion
The present results indicate that copper gluconate does not exert significant systemic toxicity, even under the current experimental conditions with exposure to multiple carcinogens, evidenced by the lack of difference in the mean bodyweights among groups and of any treatment-related changes in extrahepatic organs/tissues. Copper gluconate may, however, cause toxic and carcinogenic risks towards the liver at high doses. Granulomas were observed in the 6000 ppm groups, resulting from copper-related hepatocellular damage and subsequent inflammatory reactions to remove such cells. In the highest copper dose group, 12000 ppm, although it consisted of only 1 rat, the number and occupancy of GST-P positive lesions, putatively pr e n e o p la s ti c , a g oo d s u rr o g a te m a r k e r o f l iv e r carcinogenicity 23 , appeared to increase. These results are consistent with earlier reports in the literature. Aburto et al. reported that inflammation was induced in the liver by high dose copper sulfate administration for 13 weeks 6 . LEC rats, in which copper is accumulated in the liver at a constant level of 200 to 300 µg/g wet tissue, are known to develop serious hepatitis and hepatocellular (pre)neoplasia, and in addition, exposure of hepatocarcinogens enhances hepatotoxic and hepatocarcinogenic events occurring in LEC rats [11] [12] [13] . We suggest the hepatotoxicity and possible hepatocarcinogenicity of copper gluconate depend on the impairment of copper metabolism. In intestinal absorption, excess copper is not taken up, and when absorbed copper is metabolized mainly in the liver, the excess portion being evacuated into bile and eventually feces 27 . In the present study, black stool was observed in the 3000 ppm groups and became frequent in the high dose groups. When copper intake overwhelms the capacity of hepatic metabolism, it accumulates in the liver or spills into the blood stream 27 . In the present study, copper levels in the serum, urine and liver tended to increase at doses of copper gluconate of 6000 ppm or greater. Rodanin's staining revealed that copper was accumulated in the livers of groups given copper gluconate at 3000 ppm or greater. Taken together, these results suggest that under the current experimental conditions, copper gluconate at the dietary dose of 3000 ppm started to overwhelm the hepatic capacity to handle copper, and that the impairment of hepatic copper metabolism became evident at 6000 ppm. Thus, this impairment could have been one of the major causes of hepatotoxicity of copper gluconate seen in the present study, because liver injury was observed when copper gluconate was administered at 6000 ppm or greater, while hepatocyte proliferation, perhaps regenerative, occurred along with the hepatic copper accumulation.
MT is a cysteine-rich protein with high affinity for heavy metal ions including copper 21 . Most of the MTcopper complexes are translocated to the endoplasmic reticulum of the cytoplasm and excreted in the bile, while some of them are polymerized to form granules in cells and then secreted into the blood plasma 21 . MT acts, therefore, as a secondary cellular mechanism in a host defense response 28 . In the present study, MT began to be induced by copper gluconate at 1000 ppm, a dose lower than those required for copper accumulation in the liver, its overflow to the blood stream and induction of liver injury. It is thus indicated that MT does indeed play defensive roles against the risks introduced by copper gluconate under the current experimental conditions, and that MT is induced in a very sensitive manner, because this was seen at the lowest dose of copper gluconate in this study.
The hepatotoxicity and possible hepatocarcinogenicity of copper gluconate at high doses may be due to the accumulation of copper in the liver, but by what mechanism does the accumulated copper induce such risks? Copper is a transient metal and can serve as a catalyst reactions generating reactive oxygen species 1, 2 . Thus, oxidative stress is a good candidate mechanism, and there are reports in the literature of the induction of oxidative stress by copper, causing cellular and tissue damage, both in vitro and in vivo [7] [8] [9] [10] [11] . For instance, oxidative stress is known to be c r u c i a l l y i n v o l v e d i n t h e h e p a t o t o x i c i t y a n d hepatocarcinogenicity of LEC rats 11 . In the present study, 8-OHdG was observed in the livers of all groups, indicating carcinogen-induced oxidative DNA damage. Copper gluconate at 6000 and 12000 ppm tended to enhance 8OHdG formation in the liver, and these doses caused liver injury.
While changes were observed in the liver, no copper gluconate-related alterations were found in the other major organs/tissues. We think the liver is the main target organ of copper gluconate. One possible reason for this is that liver is the organ in which copper is mainly metabolized. Alternatively, the other organs/tissues may not have suffered from apparent copper gluconate toxicity within the short dosing period of this study. We will evaluate the effects of copper gluconate on these organs/tissues in a full-scale study using the medium-term multi-organ carcinogenesis model.
In conclusion, copper gluconate exerts effects on the liver at the relatively low dietary dose of 1000 ppm, and at 6000 ppm it exceeds the capacity of the liver to handle copper, causing hepatic injury after exposure to multiple carcinogens under conditions similar to the medium-term multi-organ carcinogenesis protocol. It is thus indicated that in a study using such a protocol, the maximum of the optimal dose range of copper gluconate should be 6000 ppm. Hepatotoxicity and possible hepatocarcinogenicity of copper gluconate may be attributable to oxidative stress induced in the liver.
